News and events
Webinar: How ctDNA can assist in critical nonoperative management decisions
Oncologists like Dr Doug Flora and Dr Debra Patt are realists. But when they began to use new tools to find cancer that surgery or treatment might have missed, something exciting happened.
Haystack Oncology and Rutgers Cancer Institute Collaborate in a Clinical Study to Examine Haystack MRD as a Guide for Post-Surgical Treatment for Lung Cancer
Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with the Rutgers Cancer Institute to evaluate the use of Haystack MRD®, a highly sensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) test, to help optimize
FDA Grants Breakthrough Device Designation for Haystack MRD Circulating Tumor DNA Test from Quest Diagnostics
Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company’s Haystack MRD® test for identifying MRD-positive patients with stage II colorectal
Mass General Brigham Launches Two Clinical Trials to Study Haystack MRD ctDNA as Guide for Post-surgical Treatment for Two Cancer Types
Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with Mass General Brigham investigators at Massachusetts Eye and Ear and Massachusetts General Hospital, world-renowned centers for head and neck and advanced cutaneous oncology. The research collaboration
Two leading oncologists take a deep dive into how groundbreaking advancements are providing a clearer crystal ball for guiding patient care
Oncologists like Dr Doug Flora and Dr Debra Patt are realists. But when they began to use new tools to find cancer that surgery or treatment might have missed, something exciting happened.
Haystack Oncology and Université de Montréal’s affiliated hospital research centre, the CRCHUM, to Deploy Haystack MRD™ Technology in Research Study for Metastatic Colorectal Cancer
Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, announced today a research collaboration with Dr. Simon Turcotte, hepatopancreatobiliary surgeon and scientist at Université de Montréal’s affiliated hospital research centre, the CRCHUM, to utilize Haystack Oncology’s personalized MRD technology (Haystack MRD™)
Recent events
We’ll be at ESMO 2025
Join us at the 2025 European Society for Medical Oncology (ESMO) Congress as we share how Haystack MRD, our tumor-informed ctDNA test, is helping redefine the role of minimal residual
Learn about Haystack MRD™ at ASCO 2025
Haystack MRD™ is proud to be part of the American Society of Clinical Oncology (ASCO) Annual Meeting, where oncology innovation takes center stage. Join us at booth #11069 to explore
Haystack MRD™ by Quest Diagnostics® at SSO 2025
We invite you to connect with us at SSO 2025 to learn how Haystack MRD can help guide treatment decisions with confidence. From the perioperative setting to recurrence surveillance, Haystack